PMID- 19104495
OWN - NLM
STAT- MEDLINE
DCOM- 20090819
LR  - 20090528
IS  - 1476-5365 (Electronic)
IS  - 0268-3369 (Linking)
VI  - 43
IP  - 10
DP  - 2009 May
TI  - Prior immunosuppressive therapy with antithymocyte globulin increases the risk of 
      EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic 
      anaemia.
PG  - 813-6
LID - 10.1038/bmt.2008.394 [doi]
AB  - We reviewed the incidence and risk factors for EBV-related post-transplant 
      lymphoproliferative disorder (EBV-PTLD) in 89 patients with acquired aplastic 
      anaemia (AAA) receiving allogeneic transplants between 1989 and 2006. The overall 
      incidence of EBV-PTLD was 6.3% (5/89) with no cases in those receiving an 
      allograft for constitutional BM failure syndromes (n=30) during the same period. 
      There was no impact of age, gender, donor status, CMV seropositivity, GVHD and 
      graft cell dose on the occurrence of PTLD. Although both reduced intensity 
      conditioning (RIC) and the prior use of antithymocyte globulin (ATG), as 
      immunosuppressive therapy (IST), were identified as the risk factors for PTLD, 
      only prior use of ATG strongly influenced the development of PTLD with an 
      incidence of 13.38+/-5.6% (5/43), compared with none in those not exposed to ATG 
      before transplantation (P=0.01) with a relative risk of 10.39 for each course of 
      prior ATG. This is the first study in patients with AAA documenting that those 
      receiving multiple prior courses of ATG are at the highest risk of developing 
      EBV-PTLD.
FAU - Buyck, H C E
AU  - Buyck HC
AD  - Department of Haematology and Stem Cell Transplantation, St George's Hospital, 
      London, UK.
FAU - Ball, S
AU  - Ball S
FAU - Junagade, P
AU  - Junagade P
FAU - Marsh, J
AU  - Marsh J
FAU - Chakrabarti, S
AU  - Chakrabarti S
LA  - eng
PT  - Journal Article
DEP - 20081222
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anemia, Aplastic/*complications/therapy
MH  - Antilymphocyte Serum/*adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects
MH  - *Herpesvirus 4, Human
MH  - Humans
MH  - Immunosuppressive Agents/*adverse effects
MH  - Incidence
MH  - Lymphoproliferative Disorders/*chemically induced/etiology/virology
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk
MH  - Risk Factors
MH  - Transplantation, Homologous
MH  - Young Adult
EDAT- 2008/12/24 09:00
MHDA- 2009/08/20 09:00
CRDT- 2008/12/24 09:00
PHST- 2008/12/24 09:00 [entrez]
PHST- 2008/12/24 09:00 [pubmed]
PHST- 2009/08/20 09:00 [medline]
AID - bmt2008394 [pii]
AID - 10.1038/bmt.2008.394 [doi]
PST - ppublish
SO  - Bone Marrow Transplant. 2009 May;43(10):813-6. doi: 10.1038/bmt.2008.394. Epub 
      2008 Dec 22.